Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.43 |
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17825296 | 1.00 | FPR2 (0.46) | FPR2MMEACEACE2KMT2A | |
| SCHEMBL28547454 | 0.90 | CA1 (0.51) | MMEACEACE2KMT2AITGB1 | |
| SCHEMBL15018831 | 0.90 | CA1 (0.51) | MMEACEACE2KMT2AITGB1 | |
| SCHEMBL17968786 | 0.89 | MME (0.47) | MMEACECTSSCTSKALDH1A1 | |
| SCHEMBL17834705 | 0.86 | CTSS (0.47) | KMT2ACTSSCTSKALDH1A1NPC1 | |
| SCHEMBL22384302 | 0.86 | CTSS (0.47) | KMT2ACTSSCTSKALDH1A1NPC1 | |
| SCHEMBL15019919 | 0.86 | MME (0.42) | MMEACEACE2ITGB1ITGA4 | |
| SCHEMBL15019922 | 0.86 | MME (0.42) | MMEACEACE2ITGB1ITGA4 | |
| SCHEMBL17825489 | 0.85 | ALDH1A1 (0.38) | FPR2MMEACEKMT2AKIFC1 | |
| SCHEMBL22384235 | 0.84 | MCL1 (0.44) | ITGA4CTSSCTSKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263826-A2 | MEANS AND METHODS FOR DETOXIFYING OCHRATOXIN A | DSM Austria GmbH (AT) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022129517-A2 | MEANS AND METHODS FOR DETOXIFYING OCHRATOXIN A | ERBER AKTIENGESELLSCHAFT (AT) | 2022-06-23 | — | — | WO | disclosed |
| CN-114645037-A | Means and methods for detoxification of ochratoxin A | 艾尔柏股份公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| EP-3230276-A1 | GLP-1 RECEPTOR MODULATORS | Celgene International II Sarl (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | FPR2 492/4885MME 796/4885ACE 3137/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | FPR2 492/4885MME 796/4885ACE 3137/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | FPR2 499/4885MME 919/4885ACE 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.